Argenx SE (ARGX)
argenx develops antibody medicines for autoimmune and neuromuscular diseases, with its main product VYVGART. It last closed at $947.52 on Nov 17, down 0.36% on the day. The average 12-month price target from 9 analysts is $1176.33 (+24.1% from the last close), with a high of $1400.00 and a low of $861.00. Analyst consensus is Strong Buy, based on the latest ratings from 9 firms (8 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 6 whale options trades in ARGX, 33% of them bullish and 67% bearish. In the past 30 days there were 6 dark pool prints totaling $9.7M, the largest $2.6M.
Key Stats
Last 12 monthsNot reported for this period.
From ARGX's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 19). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 9 analysts who set a price target on ARGX in the past 90 days. The average target is $1176.33, with a high of $1400.00 and a low of $861.00, compared with the last close of $947.52.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | Piper Sandler | Target raised | Buy | $1215 → $1350 |
| Nov 13 | Morgan Stanley | Target lowered | Buy | $1190 → $1130 |
| Oct 27 | Citigroup | Target raised | Buy | $1182 → $1232 |
| Oct 23 | Morgan Stanley | Target lowered | Buy | $1250 → $1190 |
| Oct 23 | Wells Fargo | Target lowered | Buy | $1356 → $1336 |
Technical Analysis
The stock is 3% above its 20 day and 3% above its 50 day average. It is 9% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 56). The nearest support is the Pivot at $944.85, and the nearest resistance the swing high (Jul 2) at $953.58.
| RSI (14) | 55.71 | Middle of its range | Neutral |
| MACD | 17.44 | Above its signal line | Bullish |
| Stochastic | 70.1 | Middle of its range | Neutral |
| ADX (14) | 20.3 | Weak trend | |
| Williams %R | -35.6 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 56.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +5.2% | Change over 10 sessions | Bullish |
| ATR (14) | $27.94 | Typical daily range, 3.0% of price |
| RSI (14) | 55.28 | Middle of its range | Neutral |
| MACD | 18.83 | Below its signal line | Bearish |
| Stochastic | 55.1 | Middle of its range | Neutral |
| ADX (14) | 21.4 | Weak trend | |
| Williams %R | -43.9 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 36.7 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −3.8% | Change over 10 sessions | Bearish |
| ATR (14) | $68.27 | Typical daily range, 7.2% of price |
What happened before
See how ARGX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ARGX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
Whale Options Flow
90DNo whale options trades in ARGX in the last 90 days.
Dark Pool
30DARGX Institutional Ownership
Full report →- ▲313 buying vs 188 selling
- ▼Shares held by funds -1.7%
- ▲Funds holding +39
- ▲Superinvestors: 4 added, 0 cut
- ▼Put/call 0.14 to 0.74
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 551 | 512 | +7.6% |
| In funds' top 10 | 14 | 13 | +7.7% |
| Held by funds | – | – | – |
| New / increased | 90 / 223 | 80 / 180 | +20.4% |
| Reduced / sold out | 140 / 48 | 163 / 50 | −11.7% |
| Put/call ratio | 0.74 | 0.14 | +427.4% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARGX is in one of them and how their past ARGX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ARGX in an article yet. Here's the latest on the wider market.
ARGX Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Oct 27, 2026 | Nov 10, 2026 | 14 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Oct 15, 2026 | Nov 10, 2026 | 26 d |
| Gilbert CisnerosD · CA | Buy | $15K – $50K | Oct 14, 2026 | Nov 10, 2026 | 27 d |
| Alan ArmstrongHouse | Buy | $1K – $15K | Mar 30, 2026 | Jul 21, 2026 | 113 d |
| Sean DuffyExecutive branch | Sell | $1K – $15K | Feb 11, 2025 | May 14, 2025 | 92 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Argenx SE
argenx is a biopharmaceutical company that develops antibody medicines for autoimmune and neuromuscular diseases. Its main product, VYVGART, is approved for several conditions, including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP). The company sells its medicines to patients and works with healthcare professionals, and it is developing a range of other candidates in clinical trials. It is based in Zwijnaarde.
- Headquarters
- Zwijnaarde







